Five takeaways:
1. First-quarter net sales hit $105.6 million, up 1 percent year over year.
2. Spine implant sales jumped 12.1 percent, to $25.7 million, while biologics fell 1.8 percent to $13.7 million.
3. Global spine sales were flat at $82.3 million, and global orthopedic sales were up 3.3 percent, to $23.3 million.
4. Orthofix reported a $5.8 million net loss for the quarter, and gross profit dropped to $1.7 million.
5. Orthofix expects 2021 net sales to reach $455 million to $465 million, a 12 percent to 14.4 percent increase over 2020.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
